# Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

> **NCT07434609** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Nanolattix Biotechnology Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Advanced Solid Tumor (Phase 1)

## Interventions

- **BIOLOGICAL:** T320 for Injection

## Key facts

- **NCT ID:** NCT07434609
- **Lead sponsor:** Nanolattix Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-12-01
- **Primary completion:** 2029-12-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07434609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07434609, "Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07434609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*